AstraZeneca vaccine shows 74% efficacy in large Phase 3 trial in U S, Chile and Peru: NJEM

Published Sep 30 2021 at 11:41 AM GMT
  • The COVID-19 vaccine developed by AstraZeneca PLC and Oxford University showed 74% efficacy at preventing symptomatic illness in a large late-stage trial conducted in the U S, Chile and Peru, according to data published in the New England Journal Of Medicine on Thursday.
  • The Phase 3 trial involved 32,451 participants and sought to determine the vaccine's efficacy in preventing symptomatic illness measured 15 days after the second dose.
  • The AstraZeneca vaccine has been widely used in the UK and Europe but is not yet authorized in the US The data showed the vaccine had an 83.5% estimated efficacy in participants aged 65 or older.
  • It proved safe with no serious adverse events and local and systemic reactions were generally mild or moderate, said the NJEM.
  • The trial was conducted in collaboration with the Department of Health and Human Services and the National Institutes of Health.



  • Published Sep 30, 2021 11:41 AM GMT